全文获取类型
收费全文 | 33273篇 |
免费 | 3444篇 |
国内免费 | 839篇 |
专业分类
耳鼻咽喉 | 156篇 |
儿科学 | 571篇 |
妇产科学 | 774篇 |
基础医学 | 1990篇 |
口腔科学 | 1410篇 |
临床医学 | 3862篇 |
内科学 | 4897篇 |
皮肤病学 | 580篇 |
神经病学 | 2012篇 |
特种医学 | 691篇 |
外国民族医学 | 8篇 |
外科学 | 3075篇 |
综合类 | 3522篇 |
现状与发展 | 2篇 |
预防医学 | 2663篇 |
眼科学 | 384篇 |
药学 | 5801篇 |
22篇 | |
中国医学 | 2968篇 |
肿瘤学 | 2168篇 |
出版年
2024年 | 61篇 |
2023年 | 846篇 |
2022年 | 938篇 |
2021年 | 1871篇 |
2020年 | 1594篇 |
2019年 | 1591篇 |
2018年 | 1539篇 |
2017年 | 1518篇 |
2016年 | 1401篇 |
2015年 | 1303篇 |
2014年 | 2723篇 |
2013年 | 3142篇 |
2012年 | 2037篇 |
2011年 | 2005篇 |
2010年 | 1563篇 |
2009年 | 1474篇 |
2008年 | 1537篇 |
2007年 | 1581篇 |
2006年 | 1406篇 |
2005年 | 1242篇 |
2004年 | 985篇 |
2003年 | 801篇 |
2002年 | 700篇 |
2001年 | 527篇 |
2000年 | 420篇 |
1999年 | 401篇 |
1998年 | 288篇 |
1997年 | 245篇 |
1996年 | 202篇 |
1995年 | 189篇 |
1994年 | 165篇 |
1993年 | 123篇 |
1992年 | 120篇 |
1991年 | 101篇 |
1990年 | 123篇 |
1989年 | 97篇 |
1988年 | 79篇 |
1987年 | 68篇 |
1986年 | 63篇 |
1985年 | 81篇 |
1984年 | 72篇 |
1983年 | 57篇 |
1982年 | 54篇 |
1981年 | 49篇 |
1980年 | 42篇 |
1979年 | 31篇 |
1978年 | 24篇 |
1977年 | 14篇 |
1976年 | 18篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
994.
995.
Percutaneous liver biopsy in clinical practice. 总被引:1,自引:0,他引:1
Percutaneous liver biopsy (PLB) is the standard procedure for obtaining hepatic tissue for histopathological examination, and remains an essential tool in the diagnosis and management of parenchymal liver diseases. The use of liver biopsy (LB) is increasing with the advent of liver transplantation and the progress being made in antiviral therapeutic agents. While blind percutaneous needle biopsy is the traditional technique, the use of ultrasound (US) guidance has increased considerably. Literatures were reviewed to assess the existing clinical practice of PLB with an emphasis on the technique, the operator, types of biopsy needles, quality of LB specimens and the risk of complications. The best available evidence indicates that the use of ultrasound-guided biopsy (UGB) is superior to blind needle biopsy (BNB). The odds ratios of the controlled studies showed that BNB carried a higher risk for major complications, postbiopsy pain and biopsy failure. Therefore, percutaneous LB under US control is superior to BNB and it is recommended that UGB be considered the standard of care for this important and widely used invasive procedure in the field of clinical hepatology. 相似文献
996.
一个原发性痛风家系致病易感基因染色体定位 总被引:1,自引:0,他引:1
目的 对一原发性痛风家系进行致病基因的染色体定位。方法 收集痛风家系成员的临床资料及血液样本。选择其中一典型家系为研究对象(包括6例患者,9例正常人),抽提外周血基因组DNA,进行全基因组扫描和连锁分析,初步明确致病基因所在的染色体区段。结果 在微卫星引物D4S1572处获得最大LOD值(θ=0.00时LOD=1.50),表明该痛风家系的致病基因与该位点连锁。结论 由于D4S1572位于4q25,因此该家系致病基因位于4q25附近。 相似文献
997.
To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low‐density lipoprotein (LDL) cholesterol (LDL‐C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid‐lowering agents? Copyright © 2008 Wiley Periodicals, Inc. 相似文献
998.
999.
UK prospective diabetes study (UKPDS) 总被引:6,自引:0,他引:6
UK Prospective Diabetes Study Group 《Diabetologia》1991,34(12):877-890
Summary The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25–65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3–16 years) for the glucose study and 5 years (range 2–6 years) for the hypertension study. 相似文献
1000.
E. Rubio-Gomis I. Martinez-Mir F.J. Morales-Olivas A. Martorell-Aragones V. Palop-Larrea A. Bernalte-Sesé J.C. Cerda-Mir P. Polo-Martín I. Febrer L. Aranda-Grau I. Llosa-Cortes Mª.J. Tejedor-Sanz J.C. Julia-Benito T. Alvarez-de-Laviada-Mulero Mª.V. Planelles-Cantarino E. Apolinar-Valiente M. Loriente-Tur A.M. Abella-Bazataqui B. Rodriguez-Gracia 《Allergologia et immunopathologia》2018,46(4):378-384